Hepatitis B Therapeutics Market to Hit 3.5 Billion USD in Revenues by 2021

1
Hepatitis B Therapeutics in Major Developed
Markets to 2021 - Increasing Number of Migrants
from High-Prevalence Regions to Drive Market
Growth
Published on 01 September, 2015 Number of
pages 78 Single User Price 4995
Over the 2014-2021 forecast period, the
hepatitis B market in the eight major markets is
expected to increase in value at a CAGR of 2.3
from 2.9 Billion to 3.5 Billion.
2
Summary of the ReportHepatitis B is an
infectious liver disease caused by the Hepatitis
B Virus (HBV) and characterized by acute or
chronic inflammation of the liver. Despite its
status as a vaccine-preventable disease, it
remains a serious global health concern.
Incidence tends to be higher in countries with a
significant number of migrants from medium and
high-prevalence countries. Approximately 350
million people worldwide are infected with
chronic hepatitis B, which causes significant
morbidity and mortality. Around 780,000 patients
die from hepatitis B each year, of which 650,000
deaths are due to complications such as cirrhosis
and liver cancer. Despite this, diagnosis and
treatment rates are poor, stemming from its
asymptomatic nature. Globally, the hepatitis B
therapeutics market is served moderately well by
the available products, of which Baraclude and
Viread are the most frequently prescribed.
However, both have received black-box warnings
from the US Food and Drug Administration (FDA),
meaning that the market has a high level of unmet
need.
Click Here To Check Complete Report
3

• Scope of the Report
• The current hepatitis B market contains mainly
  nucleoside analog reverse transcriptase
  inhibitors, nucleotide analogs, and interferon's
  -
• Will these drugs continue to dominate hepatitis B
  treatment?
• With 81 active pipeline molecules, most of the
  investigational drug candidates are small
  molecules and vaccines, comprising 64 of the
  pipeline -
• What are the most prominent small molecules and
  vaccines in the pipeline?
• Do the pipeline molecules offer advantages over
  commercially proven mechanisms?
• Analysis of clinical trials since 2006 has
  identified a high rate of attrition in hepatitis
  B products -
• How do failure rates vary by product stage of
  development, molecule type, and mechanism of
  action?
• How do other factors such as average trial
  duration and trial size influence the costs and
  risks associated with product development?
• Over the 2014-2021 forecast period, the hepatitis
  B market in the eight major markets is expected
  to increase in value at a CAGR of 2.3 from 2.9
  billion to 3.5 billion -
• Which markets make the most significant
  contribution to the current market size?
• What are the epidemiology trends in these markets?

Download Sample Brochure
4

• Reasons to buy
• This report will enable you to -
• Understand the clinical context of hepatitis B by
  considering symptoms, etiology, pathophysiology,
  epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products,
  and companies that dominate the current marketed
  products landscape and recognize gaps and areas
  of unmet need.
• Appreciate key pipeline trends by molecule type,
  route of administration, mechanism of action, and
  novelty.
• Consider market opportunities and potential risks
  by looking at trends in clinical trial size,
  duration, and failure rate by stage of
  development, molecule type, and mechanism of
  action.
• Recognize the late-stage pipeline molecules that
  have demonstrated strong therapeutic potential by
  examining clinical trial data and multi-scenario
  product forecast projections.
• Compare treatment usage patterns, annual therapy
  costs, and market growth projections for the US,
  Canada, the UK, France, Germany, Italy, Spain,
  and Japan.
• Discover trends in licensing and co-development
  deals concerning hepatitis B products and
  identify the major strategic consolidations that
  have shaped the commercial landscape.

Make an Inquiry Before Buying
5
Hepatitis B Therapeutics in Major Developed
Markets to 2021 - Increasing Number of Migrants
from High-Prevalence Regions to Drive Market
Growth
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Hepatitis B Therapeutics Market are provided
in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Hepatitis B
Therapeutics Market Report